Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat” signal to macrophages. High expression of CD47 by tumor cells has been correlated with more aggressive disease and poor survival. SIRPαFc is initially being developed […]
The Reality for Mannkind
Mannkind, the maker of the inhaled insulin product Afrezza, is the 11th best performing biotech stock according to Finviz in the last month, up 62%. That performance is in line with several big ASCO winners such as Oncothyreon, Ignyta and Immunogen. Also on the list is DMD company Sarepta, which has new hope for an […]
13F Analysis of Best Performing Healthcare Hedge Funds (Q1 2015)
13F filings have arrived and it’s like Christmas day for me. I’ve been pouring through the filings, tweeting the interesting ones, and probably annoying everyone on twitter. These filings are a great idea generation tool, a starting place for due diligence, and way to get a peek at the focus of the best minds in […]
Chimera Research Group Catalyst Summary for April 2015
At the end of each month Chimera Research Group provides you with a monthly summary of ten notable catalysts/events that have been completed during the past month. APRIL 2015: Gilead Sciences (NASDAQ: GILD) exceeded analyst expectations reporting $7.6 billion in first quarter revenue , including $4.55 billion from their HCV portfolio of Harvoni and Sovaldi. Revenue […]
The Week Ahead in Earnings
A second busy week of earnings is due out in the space this week. We will see 3 of the 4 remaining large caps report (Gilead, Celgene, Vertex) and a smattering of big pharma reports as well. Given the sell off today, earnings reports could stem the fall, or exacerbate it further with poor results. […]
CYNAF is OFF the Mark
Cynapsus is developing a sublingual film formulation of apomorphine for the treatment of acute “Off” episodes in patients with Parkinson’s Disease resulting from long term use of Levodopa. While Levodopa is considered the single best treatment for Parkinson’s, long term use of the medicine leads to motor fluctuations as its efficacy declines. Patients then begin […]
Chimera Research Group Catalyst Summary for March 2015
At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that the FDA approved the expanded use of Opdivo to treat patients with advanced squamous non-small cell lung cancer (NSCLC). Approval came just over two […]
BMY – Is the Technical Correction Done ?
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high $69.20 in March, 20th 2015, getting a boost from the fastest FDA approval I ever seen. On Febreuary 27th 2015 the FDA granted Priority Review […]
Adamas Pharmaceuticals: two interesting programs for Alzheimer and Parkinsons Diseases
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas (ADMS) is a company focused on CNS diseases, specifically Parkinson’s (PD) and Alzheimer’s Diseases (AD). It has a low market cap (~$300M), plenty of cash ($158M), low float with most of the shares (64.2%) held by insiders and institutions (link), two FDA approved products partnered with Forest/Actavis (for one […]
Adamas Pharmaceuticals – Volatility Squeeze Action
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas pharmaceutical had its initial public offering last year April 10th, the closing of its IPO of 3 million shares at a public offering price of $16.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol “ADMS” on April 10, 2014. Adamas had […]
March 13 Biotech Update
I know that the sector is doing well and near highs but I cannot shake the feeling that the stocks feel heavy. I do not have a better way to describe it nor anything more solid than this impression. Perhaps this is simply the wall of worry that we are going to climb. If I […]
Quick Take on Marinus Pharmaceuticals
Marinus Pharmaceuticals is developing the allopregnanolone analog Ganaxolone as a treatment for epilepsy and other seizure disorders. Its most advanced program is a multinational P3 trial of patients with refractory focal onset seizures. The drug is also being tested in patients with Fragile X syndrome and in girls with epilepsy due to PCDH19 mutation. The […]
Chimera Research Group Catalyst Summary for February 2015
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. February 2015: GILD provided detailed results of their Phase 3 once-daily single tablet regimen of tenofovir alafenamide (TAF) for the treatment of HIV-1 infection. The data showed that it was found […]
Pfenex: Biosimilar Enthusiasm Is High
San Diego’s Pfenex Inc. is riding the market’s enthusiasm for biosimilars, molecules that although not considered identical, can be automatically substituted for biologic drugs. Previously considered immune to generic competition, recent regulatory changes have cleared the path to entry for copycats of so-called large molecule compounds. A looming patent cliff in 2020 puts about $100 […]
Quick update: The IBB – Negative Divergence
iShares Nasdaq Biotechnology (IBB) – Nasdaq As tweeted several time last and early this week, signs of weakness in the IBB Signs of weakness in the $IBB ..Start forming a Bearish “Rising Wedge” ..only if breaking down the lower line & 50MA pic.twitter.com/MPmn1DNF2T — Joe (@GantosJ) February 2, 2015 The “Rising Wedge” is a bearish pattern, […]
Chimera Research Group Catalyst Summary for January 2015
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. JANUARY 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that their Phase 3 CheckMate-017 trial evaluating Opdivo versus docetaxel for the treatment of refractory squamous cell non-small cell lung cancer […]
Revisiting the Bubble Debate
With this week’s moves in the market and with the JP Morgan Healthcare conference finished, I think its time to bring up the debate again about whether or not biotech may be in a bubble. While most are familiar with the outstanding sector performance, lets just put it into context a bit. Since the March […]
CBSTZ: New developments for Cubist CVR
A quick update on CBSTZ the Cubist CVR. Today Cubist filed an 8-K notifying CVR holders that it intends to purchase all the CVRs at $0.059225 on February 2, 2015. This is known as a “Failure Purchase Notice”. Below is a link to the 8-K: http://www.sec.gov/Archives/edgar/data/912183/000110465915000010/a14-26868_48k.htm This outcome is listed as a possibility in the […]
Chimera Research Group Catalyst Summary for December 2014
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. DECEMBER 2014: 1) AbbVie (NYSE:ABBV) announced that the FDA approved Viekira Pak (ombitasvir/paritaprevir/ritonavir & dasabuvir), their next generation oral treatment for patients with chronic genotype 1 (GT1) hepatitis C […]
CBSTZ: a low probability, high impact special situation
This week started with a merger Monday. Cubist Pharmaceuticals agreed to be acquired by Merck & Company for $9.5B including assumption of debt. CBST traded like one would expect on Monday, just below the offer price. However, a Contingent Value Right (CVR) with the ticker CBSTZ traded up to $0.081 on Monday, which represents a […]
